GILD
Price
$114.50
Change
+$1.32 (+1.17%)
Updated
Aug 4, 04:59 PM (EDT)
Capitalization
90.79B
3 days until earnings call
GRFS
Price
$10.72
Change
-$0.06 (-0.56%)
Updated
Aug 4, 04:59 PM (EDT)
Capitalization
5.48B
94 days until earnings call
Interact to see
Advertisement

GILD vs GRFS

Header iconGILD vs GRFS Comparison
Open Charts GILD vs GRFSBanner chart's image
Gilead Sciences
Price$114.50
Change+$1.32 (+1.17%)
Volume$125.61K
Capitalization90.79B
Grifols SA
Price$10.72
Change-$0.06 (-0.56%)
Volume$33.9K
Capitalization5.48B
GILD vs GRFS Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. GRFS commentary
Aug 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a StrongBuy and GRFS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 05, 2025
Stock price -- (GILD: $114.51 vs. GRFS: $10.72)
Brand notoriety: GILD: Notable vs. GRFS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 78% vs. GRFS: 58%
Market capitalization -- GILD: $90.79B vs. GRFS: $5.48B
GILD [@Pharmaceuticals: Major] is valued at $90.79B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 4 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • GILD’s FA Score: 4 green, 1 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, GILD is a better buy in the long-term than GRFS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 4 TA indicator(s) are bullish while GRFS’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 4 bullish, 3 bearish.
  • GRFS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GILD is a better buy in the short-term than GRFS.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а +1.31% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +6.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.39%. For the same industry, the average monthly price growth was +8.22%, and the average quarterly price growth was +15.21%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

GRFS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($90.8B) has a higher market cap than GRFS($5.48B). GRFS has higher P/E ratio than GILD: GRFS (68.68) vs GILD (16.20). GRFS YTD gains are higher at: 44.892 vs. GILD (24.265). GILD has higher annual earnings (EBITDA): 10.5B vs. GRFS (640M). GILD has more cash in the bank: 7.26B vs. GRFS (544M). GRFS has less debt than GILD: GRFS (11.1B) vs GILD (25B). GILD has higher revenues than GRFS: GILD (27.1B) vs GRFS (6.54B).
GILDGRFSGILD / GRFS
Capitalization90.8B5.48B1,658%
EBITDA10.5B640M1,641%
Gain YTD24.26544.89254%
P/E Ratio16.2068.6824%
Revenue27.1B6.54B415%
Total Cash7.26B544M1,335%
Total Debt25B11.1B225%
FUNDAMENTALS RATINGS
GILD vs GRFS: Fundamental Ratings
GILD
GRFS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
15100
SMR RATING
1..100
2982
PRICE GROWTH RATING
1..100
2138
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GILD (22) in the Biotechnology industry. This means that GRFS’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (15) in the Biotechnology industry is significantly better than the same rating for GRFS (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than GRFS’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for GRFS (82) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than GRFS’s over the last 12 months.

GILD's Price Growth Rating (21) in the Biotechnology industry is in the same range as GRFS (38) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as GILD (100) in the Biotechnology industry. This means that GRFS’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDGRFS
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
42%
Bearish Trend 4 days ago
65%
Momentum
ODDS (%)
Bullish Trend 4 days ago
53%
Bullish Trend 4 days ago
71%
MACD
ODDS (%)
Bullish Trend 4 days ago
62%
Bullish Trend 4 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
47%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
58%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 18 days ago
50%
Bearish Trend 18 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
53%
Bearish Trend 4 days ago
75%
Aroon
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ISHG75.051.29
+1.75%
iShares 1-3 Year International TrsBd ETF
BAUG46.70-0.45
-0.95%
Innovator U.S. Equity Buffer ETF Aug
JULZ43.68-0.52
-1.18%
Trueshares Structured Outcome July ETF
SDVY35.47-0.57
-1.58%
First Trust SMID Cp Rising Div Achv ETF
USOY8.90-0.19
-2.14%
Defiance Oil Enhanced Options Income ETF

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.79%
BMY - GILD
50%
Loosely correlated
+2.12%
GSK - GILD
46%
Loosely correlated
+1.10%
PFE - GILD
43%
Loosely correlated
+0.86%
NVS - GILD
43%
Loosely correlated
+1.37%
SNY - GILD
43%
Loosely correlated
+2.43%
More

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.75%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
+0.86%
BIIB - GRFS
28%
Poorly correlated
+3.09%
GILD - GRFS
28%
Poorly correlated
+0.79%
More